New Generation mRNA Booster Vaccine Against Emerging VOCs

April 10, 2023 updated by: Stemirna Therapeutics

A Multi-national, Randomized, Observer-blinded, Parallel Controlled Trial to Evaluate the Immunogenicity and Safety of New Generation COVID-19 mRNA Booster Vaccination Against Emerging Variants of Concern (VOC)

Primary：Objectives ：SafetyTo describe the safetyprofile of all participants in each group up to 6months post-dose.Immunogenicity：To demonstrate the superiorityof neutralizing antibodyresponse in terms of geometric mean titers (GMT) of mRNA vaccine compare with inactive vaccine28 days post dose. Secondary:Immunogenicity

  1. To describe binding antibodyprofile at D01,D08, D15, D29,D91 and D181 of eachstudy group.
  2. To describe the neutralizing antibody profile atD08,D15,D91 and D181of 600 participants for each studyintervention group. Exploratory:Cell-mediated immunity To describe the cellular immuneresponse profile at D01, D08, D15and D29, in a subset of 30 participants for each study group.

Efficacy:To describe the occurrence of virologically-confirmed COVID-19 like illness and serologically confirmed SARS-CoV-2 infection.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Detailed Description

Endpoints:Safety Endpoints- Occurrence of unsolicited systemic AEs reported in the 30 minutes after each injection.

Occurrence of solicited injection site reactions and systemicreactions occurring up to 7 days post-dose.

Occurrence of unsolicited non-serious AEs reported up to 28 dayspost-dose. Occurrence of SAEs and AESIs up to 6 months throughout the study. Immunogenicity Endpoints:GMT of neutralizing antibody will be measured with the neutralization assayon D01,D29.

Binding antibody titers to full length SARS-CoV-2 Spike (S) protein will be measured for each study intervention group with the ELISA method

  • Antibody titer on D01, D08, D15, D29, D91, D181
  • Fold-rise in antibody titer at D08, D15, D29, D91 and D181 post vaccination relative to D01
  • 4-fold-rise in antibody titer at D08, D15, D29, D91, and D181 relative to D01 Neutralizing antibody titers will be measured with the neutralization assay
  • Antibody titer on D08, D15, D29, D91 and D181
  • Fold-rise (fold rise in serum neutralization titer post vaccination relative to D01) at D08, D15, D29, D91 and D181
  • 4-fold rise in serum neutralization titer [post/pre] relative to D01 at D08, D15, D29, D91 and D181
  • Occurrence of neutralizing antibody seroconversion, defined as baseline values below LLOQ at baseline with detectable neutralization titer above assay lower limit of quantification at D08, D15, D29, D91 and D181INF-γ, IL-4 and IL-2 will be measured in whole blood and/or cryopreserved PBMC following stimulation with pools of S
  • ExploratoryCell-mediated immunity To describe the cellular immune response profile at D01, D08, D15 and D29, in a subset of 30 participants for each study group antigen peptides.

Virologically-confirmed COVID 19 like illness as defined by specified clinical symptoms and signs and confirmed by a positive result for SARS-CoV-2 nucleic acid viral detection assay.

Study Type

Interventional

Enrollment (Anticipated)

2000

Phase

  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

16 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  1. Participant is willing and able to give written informed consent for participation in the study.
  2. Male or Female, aged 18 years or above and in good health as determined by study clinician.
  3. Female participants of childbearing potential must be willing to ensure that they or their partner use effective contraception from 1 month prior to first immunization continuously until 3 months after boost immunization.
  4. In the Investigator's opinion, is able and willing to comply with all trial requirements.
  5. Subjects had completed the 2-dose series vaccination of COVID-19 inactivated vaccine at least .

24 weeks with the completed the 2-dose Series as the primary vaccination according to the product label.

Exclusion Criteria:

The participant may not enter the study if ANY of the following apply:

  1. Confirmed cases, suspected cases or asymptomatic cases of COVID-19;
  2. Self-reported history of SARS and MERS infection;
  3. Receipt of live attenuated vaccine within one month prior to vaccination and other vaccines within 14 days prior to vaccination;
  4. Receipt of any SARS-COV-2 vaccine after last dose of primary vaccination
  5. Participants who are pregnant at enrolment or planning to become pregnant during the first 3 months following vaccination.
  6. Administration of immunoglobulins and/or any blood products within the three months preceding the planned administration of the vaccines.
  7. History of allergic disease or reactions likely to be exacerbated by any component of study vaccines.
  8. Any history of anaphylaxis to any component of vaccine.
  9. Bleeding disorder (e.g. factor deficiency, coagulopathy or platelet disorder), or continuous use of anticoagulants (warfarin, apixaban, rivaroxaban, dabigatran, edoxaban), or prior history of significant bleeding or bruising following IM injections or venipuncture.
  10. Suspected or known current alcohol or drug dependency
  11. Any other significant disease, disorder or finding which may significantly increase the risk to the volunteer because of participation in the study, affect the ability of the volunteer to participate in the study or impair interpretation of the study data.
  12. Severe and/or uncontrolled cardiovascular disease, respiratory disease, gastrointestinal disease, liver disease, renal disease, endocrine disorder, and neurological illness (mild/moderate well controlled comorbidities are allowed).
  13. Scheduled elective surgery during the trial.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Quadruple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: SW-BIC-213
Intervention Name :COVID-19 mRNA vaccine Type :Investigational Vaccine Dose :Formulation mRNA Unit Dose Strength(s) :0.5ml; Dosage Level(s) :0.25ml; Route of Administration: injection Intramuscular
Biological: SW-BIC-213
The patient will take a single 25 μg dose mRNA vaccine SW-BIC-213.
Active Comparator: SARS-Cov-2 Vaccina(Vero Cell ) Inactivated
Intervention Name: COVID-19 Inactivated Vaccine Type : Control Vaccine Dose :Inactive Unit Dose Strength(s) : 0.5ml; Route of Administration Intramuscular : injection Intramuscular
Biological: SARS-Cov-2 Vaccina(Vero Cell ) Inactivated
The patient will take a third dose of COVID-19 Inactivated vaccine.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Number of participants with treatment-related adverse events as assessed by CTCAE v5.0
Time Frame: 6 months post-dose
To describe the safety profile of all participants in each group up to 6 months post-dose.
6 months post-dose
Immunogenicity of 28 days post dose
Time Frame: 28 days post dose
To demonstrate the superiority of neutralizing antibody response in terms of geometric mean titers (GMT) of mRNA vaccine compare with inactive vaccine 28 days post dose.
28 days post dose

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Stemirna Therapeutics

Investigators

  • Principal Investigator: Mayfong Mayxay, doctor, National Ethics Committee for Health Research(NECHR)

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Anticipated)

October 1, 2022

Primary Completion (Anticipated)

May 11, 2023

Study Completion (Anticipated)

May 11, 2023

Study Registration Dates

First Submitted

October 8, 2022

First Submitted That Met QC Criteria

October 11, 2022

First Posted (Actual)

October 14, 2022

Study Record Updates

Last Update Posted (Actual)

April 12, 2023

Last Update Submitted That Met QC Criteria

April 10, 2023

Last Verified

April 1, 2023

More Information

Terms related to this study

Keywords

Other Study ID Numbers

  • SWC310

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Efficacy

Clinical Trials on SW-BIC-213

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Malta

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe